Apr 24, 2026｜2026
Henlius' Phase 2/3 Trial of Pimurutamab (HLX07) in Combination with Serplulimab for Advanced sqNSCLC Completes CTN in Australia
Henlius (2696.HK) today announced that a randomized, double-blind, multicentre, parallel-controlled Phase 2/3 clinical trial evaluating its self-developed recombinant anti-EGFR mAb pimurutamab (HLX07) in combination with the anti-PD-1 mAb serplulimab (trade name: Hetronifly® in Europe) and chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (sqNSCLC) has completed Clinical Trial Notification (CTN) in Australia, marking a crucial step in exploring innovative treatments for first-line treatment of sqNSCLC.
Addressing Unmet Needs in sqNSCLC: Clinical Potential of EGFR Overexpression
Lung cancer remains the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and comprises both squamous and non-squamous subtypes.¹ Squamous NSCLC (sqNSCLC) represents approximately 20%–30% of NSCLC cases and is generally associated with poorer clinical outcomes compared with non-squamous disease.² Epidermal growth factor receptor (EGFR) is widely overexpressed across multiple solid tumours, including both squamous and non-squamous NSCLC, and is considered a key driver of tumour initiation, progression, and treatment resistance.³ Globally, EGFR overexpression has been reported in approximately 40%–89% of patients with NSCLC, depending on histological subtype and ethnic background, suggesting that millions of newly diagnosed patients each year may fall within this population.⁴⁻⁶ Among patients with sqNSCLC, the prevalence of EGFR overexpression is even higher, approaching 90%.⁴⁻⁵ Given the widespread expression of EGFR in this population, the exploration of EGFR pathway–based combination strategies as first-line treatment approaches for the broader sqNSCLC population is supported by strong biological rationale and meaningful clinical investigational value.
It is noteworthy that EGFR overexpression is distinct from EGFR sensitizing mutations, with relatively low correlation between the two.⁷ In particular, classical sensitizing EGFR mutations are rare among patients with sqNSCLC.⁸ As a result, the majority of patients with EGFR-overexpressing squamous tumours do not harbour sensitizing EGFR mutations and are therefore unlikely to benefit from EGFR tyrosine kinase inhibitors (TKIs).⁸ Previous studies have demonstrated that anti-EGFR mAbs in combination with chemotherapy may provide clinical benefit in the treatment of squamous malignancies, including squamous NSCLC.⁹⁻¹⁰ In recent years, immunotherapy-based regimens combining PD-1/PD-L1 inhibitors with chemotherapy have significantly improved first-line treatment outcomes for patients with advanced sqNSCLC and have become one of the current standards of care.¹¹⁻²⁰ However, despite advances achieved with both targeted therapy–chemotherapy combinations and immunotherapy–chemotherapy regimens, overall efficacy gains remain limited¹¹⁻²¹, highlighting an urgent need for novel therapeutic strategies to further improve treatment outcomes and extend the durability of clinical benefit.
A Targeted and Immunotherapy Combination Strategy with Promising Clinical Activity
Pimurutamab is a humanized anti-EGFR mAb developed by Henlius, featuring reduced immunogenicity and enhanced binding affinity to the EGFR target. Through Fc engineering, pimurutamab demonstrates a significantly prolonged half-life, and the 3-week dosing frequency makes it more suitable for clinical use in combination with immunotherapies. Preclinical trials have shown that, compared with existing anti-EGFR mAbs, pimurutamab exhibits improved biological activity, significantly inhibiting tumour cell growth across multiple tumour models and demonstrating strong synergistic effects when combined with serplulimab.²² The combination not only blocks EGFR-mediated proliferative signalling but also simultaneously enhances antitumor immune responses, highlighting its promising potential as a synergistic combination therapy.
Positive results have been reported from a Phase 2 dose-exploration trial (HLX07-sqNSCLC-201) evaluating pimurutamab in combination with serplulimab and chemotherapy as a first-line treatment for patients with EGFR-overexpressing advanced or metastatic sqNSCLC. Updated data with median follow-up durations of 18.6 months and 23.5 months were successively presented at the 2025 World Conference on Lung Cancer (WCLC) and the International Summit on Frontiers and Innovations in Lung Cancer held in November 2025. Based on the latest analysis with a median follow-up of 23.5 months, the regimen demonstrated stable and durable antitumor activity across both dose cohorts, with an objective response rate (ORR) of approximately 70% and a disease control rate (DCR) exceeding 90%. In the high-dose cohort, median progression-free survival (mPFS) reached 17.4 months, while mPFS in the low-dose cohort had not yet been reached at the time of analysis. Median overall survival (mOS) and median duration of response (mDOR) remained immature in both cohorts. The overall safety profile was manageable, with no new safety signals observed.
This study (HLX07-sqNSCLC-301) is a randomized, double-blind, multicentre, parallel-controlled Phase 2/3 clinical study designed to evaluate pimurutamab in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab or pembrolizumab and chemotherapy as first-line treatment in patients with advanced sqNSCLC. The study consists of two parts. Part I is a Phase 2 study, in which participants will be randomized in a 1:1:1 ratio to one of the three groups: Group A: pimurutamab 1000 mg in combination with serplulimab and chemotherapy; Group B: pimurutamab 600 mg in combination with serplulimab and chemotherapy; and Group C: placebo in combination with serplulimab and chemotherapy. Treatment will be administered once every 3 weeks (Q3W) for a total of 4 cycles, followed by maintenance therapy with the corresponding dose of pimurutamab or placebo in combination with serplulimab. The primary endpoints of Part I are progression-free survival (PFS) and objective response rate (ORR), as assessed by Blinded Independent Central Review (BICR). Part II is a Phase 3 study, and the dose of pimurutamab in Part II will be determined based on the results of Part I. Participants will be randomized in a 1:1 ratio to one of two groups. Experimental group: pimurutamab in combination with serplulimab and chemotherapy, administered Q3W for 4 cycles, followed by maintenance therapy with HLX07 in combination with serplulimab. Control group: placebo in combination with pembrolizumab and chemotherapy, administered Q3W for 4 cycles, followed by maintenance therapy with placebo in combination with pembrolizumab. The primary endpoints of Part II are PFS assessed by BICR, and overall survival (OS). The primary objective of this study is to evaluate the efficacy of pimurutamab in combination with serplulimab and chemotherapy versus placebo in combination with serplulimab or pembrolizumab and chemotherapy as first-line treatment in patients with advanced sqNSCLC. Secondary objectives include evaluating the safety, pharmacokinetic (PK) characteristics, and immunogenicity of pimurutamab in combination with serplulimab and chemotherapy, as well as evaluating the relationship between EGFR and PD-L1 expression in tumour tissues and efficacy.
Henlius has established a comprehensive portfolio in the field of lung cancer, spanning multiple histological subtypes and treatment stages, and incorporating diverse therapeutic mechanisms including immunotherapy, targeted therapy, anti-angiogenic therapy, and antibody–drug conjugates (ADCs). The Company’s flagship product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti-PD-1 monoclonal antibody approved for first-line treatment of small cell lung cancer (SCLC). It has been approved in more than 40 countries and regions worldwide, covering key first-line indications across lung cancer, including extensive-stage small cell lung cancer (ES-SCLC), squamous non-small cell lung cancer (sqNSCLC), and non-squamous non-small cell lung cancer (nsqNSCLC). In addition, the global Phase 3 multicentre clinical trial evaluating serplulimab for first-line treatment of limited-stage small cell lung cancer (LS-SCLC) has completed global patient enrolment. Meanwhile, HLX04 (bevacizumab biosimilar) further strengthens the company’s anti-angiogenic therapy portfolio in lung cancer, providing a high-quality and more affordable treatment option for patients with advanced, metastatic, or recurrent NSCLC. On the innovation front, Henlius is advancing a diversified pipeline with differentiated mechanisms of action. HLX43, a PD-L1-targeting ADC with broad anti-tumour potential and considered a potential best-in-class candidate, has demonstrated a compelling “high efficacy, low toxicity” profile across multiple tumour types including lung cancer, and clinical trials have been initiated in China, the United States, Japan, and Australia. In addition, the combination regimen of the anti-EGFR mAb pimurutamab with serplulimab has shown breakthrough clinical signals in EGFR-high-expressing sqNSCLC, further advancing precision treatment strategies. The Company’s early-stage pipeline also includes HLX3901, a DLL3 × DLL3 × CD3 × CD28 tetravalent T-cell engager being developed for SCLC, and HLX48, a bispecific ADC targeting EGFR × cMet for the treatment of NSCLC.
Looking ahead, Henlius will continue to deepen its innovation strategy in lung cancer, leveraging a diversified product portfolio and global clinical development capabilities to deliver more breakthrough treatment options for patients and generate greater clinical and societal value.
References
1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–63.
2. Wang Y, Safi M, Hirsch FR, et al. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat Rev Clin Oncol 2025; 22: 200–14.
3. Normanno N, De Luca A, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16. DOI: 10.1016/j.gene.2005.10.018. PMID: 16377102.
4. Prabhakar CN. Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res. 2015;4(2):110-118. doi:10.3978/j.issn.2218-6751.2015.01.01
5. Karlsen E-A, Kahler S, Tefay J, Joseph SR, Simpson F. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells. 2021; 10(5):1206. http://doi.org/10.3390/cells10051206
6. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012). http://doi.org/10.1038/nature11404
7. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, Colasacco C, Dacic S, Hirsch FR, Kerr K, Kwiatkowski DJ, Ladanyi M, Nowak JA, Sholl L, Temple-Smolkin R, Solomon B, Souter LH, Thunnissen E, Tsao MS, Ventura CB, Wynes MW, Yatabe Y. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018 Mar;142(3):321-346. doi: 10.5858/arpa.2017-0388-CP. Epub 2018 Jan 22. PMID: 29355391.
8. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525 (2012). http://doi.org/10.1038/nature11404
9. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009 May 2;373(9674):1525-31.
10. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012 Jan;13(1):33-42.
11. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379: 2040–51.
12. Gogishvili M, Melkadze T, Makharadze T, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022; 28: 2374–80.
13. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198–211.
14. Johnson ML, Cho BC, Luft A, et al, and the POSEIDON investigators. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol 2023; 41: 1213–27.n
15. Wang J, Lu S, Yu X, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: a phase 3 randomized clinical trial. JAMA Oncol 2021; 7: 709–17.
16. Ren S, Chen J, Xu X, et al, and the CameL-sq Study Group. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol 2022; 17: 544–57.
17. Zhou C, Wang Z, Sun Y, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 2022; 23: 220–33.2
18. Zhong H, Sun S, Chen J, et al. First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial. Lancet Respir Med 2024; 12: 355–65.
19. Zhou C, Wu L, Fan Y, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol 2021; 16: 1501–11.
20. Zhou C, Hu Y, Arkania E, et al, and the ASTRUM-004 Investigators. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004). Cancer Cell 2024; 42: 198–208.e3.
21. Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, Enriqueta Felip, Christian Valencia, Egbert F. Smit,The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer, Cancer Treatment Reviews, Volume 122, 2024, 102664, ISSN 0305-7372, http://doi.org/10.1016/j.ctrv.2023.102664.
22. Tseng,Yun-Chih Cheng, Chieh-Hsin Ho, Shih Chieh Chen, Yanling Wang, Eugene Liu,Hassan Issafras & Weidong Jiang (2021) Distinguishing features of a novelhumanized anti-EGFR monoclonal antibody based on cetuximab with superiorantitumor efficacy, Expert Opinion on Biological Therapy, 21:11, 1491-1507.
Back
Privacy Policy
Cookies Policy
Accessibility
Terms of Use
Privacy Policy
Introduction
Shanghai Henlius Biotech, Inc., and, where applicable, its affiliates and subsidiaries (collectively, “we” , “us” or “our”) attach great importance to the protection of your privacy and personal information. This Privacy Notice (this “Policy”) is formulated in accordance with applicable PRC laws and regulations governing the protection of personal information in the People’s Republic of China (“PRC”).
This Policy applies when: (1) you browse or use our website and other online resources (such as our WeChat official accounts); (2) subscribe to our news or announcements; or (3) contact us through the contact details or other interactive features made available on our website, or otherwise interact with us through our website.. The purpose of this Policy is to explain how and why we process your personal information, the types of personal information involved, applicable retention periods, your rights, and the measures we take to protect personal information. Please read this Policy carefully to ensure that you fully understand its content.
In certain business scenarios, we may provide additional explanations regarding the processing of your personal information through separate agreements, privacy statements, or personal information notices. In the event of any inconsistency, such documents shall prevail. For example, where a recruitment function is provided through a third-party platform or service, the relevant third party privacy policy or notice may also apply.
For the purposes of this Policy, “personal information” refers to all kinds of information related to identified or identifiable natural persons, excluding anonymized information.
We collect, use, store, transfer and otherwise process personal information in strict compliance with applicable PRC laws and regulations of the People’s Republic of China.
Our website may contain links to third party websites for your convenience. We do not control, and are not responsible for, the privacy practices of such third parties. We encourage you to review their privacy policies before using those websites.
If you have any questions or concerns regarding this Policy or our processing of personal information, please contact us using the details provided below.
This Policy will help you understand:
I. How we collect your personal information
II. How we use your personal information
III. How we entrust, share, transfer and publicly disclose your personal information
IV. Cross border transfer of personal information
V. How we store your personal information
VI. Security measures
VII. Your rights
VIII. Personal information of minors
IX. Updates to this Policy
X. How to contact us
I. How do we collect your personal information?
In addition to our employees, we may process personal information of the following persons:
• Visitors and users of our website;
• Healthcare Professionals;
• Investigators of clinical trial institutions and personnel of contract research organizations in clinical trials;
• Subjects of clinical trials and their relatives;
• Consumers/patients and their relatives using our products or services;
• Staff of business partners (including vendors, distributors, partners, etc.); and
• Our applicants.
We may process personal information of website visitors and individuals who contact or interact with us through our website or other online resources. Depending on the relevant page, function, or interaction, separate privacy notices, consents, platform privacy policies, contracts, or other notices may apply.
Based on the context in which you interact with us, we may collect personal information by the following means and on the legal bases permitted by applicable PRC laws and regulations, including your consent, the necessity for entering into or performing a contract, compliance with legal obligations, protection of life, health or property, public health needs, or other circumstances permitted by law:
• Your personal information provided to us voluntarily
When you subscribe to our news or announcements, contact us through the contact details or other interactive features made available on our website, a third-party platform or service linked or referred to on our website, or otherwise communicate with us in relation to our website, we may collect the personal information that you voluntarily provide, such as your name, contact details, organization, and the content of your inquiry or request, depending on the relevant page or function.
• Personal information collected by us independently through our website and other online channels
When you visit our website, most of our services do not require any registration, and you can visit our website without telling us who you are. However, some pages or functions may require you to provide certain personal information. If you choose not provide such information as we request, you may not be able to access certain content or functions or we may not be able to respond to your inquiry, request or subscription. Please refer to the relevant page or notice for further details about the categories of personal information collected in a specific scenario.
• Personal information we collect from vendors or business partners
In the course of our daily business operations, we may collect personal information from our vendors or business partners. We require our vendors and business partners to comply with the requirements of the personal information protection laws and regulations of the PRC and to lawfully provide us with personal information. If you are an employee or representative of one of our vendors or business partners, we may collect personal information such as your name and contact details for the purpose of establishing business contacts and cooperations.
• Personal information we collect from publicly available sources
We may collect personal information of medical and healthcare professionals from such publicy available sources, such as the official websites of medical institutions and the official websites of competent government departments, and process such information within a reasonable scope and for lawful purposes. For example, for the purpose of lawful academic or professional interaction with healthcare professionals, we may collect the name, gender, employer, position, practitioner registration information, academic title, degree, educational background, specialty expertise, and profile information, where such information has been lawfully made public.
Our website may include links, contact details, QR codes, or references to third-party platforms or services. Where you choose to interact with us through such third-party platforms or services, the relevant third party may also process your personal information in accordance with its own privacy policy and applicable law, and we encourage you to review such policy before submitting your information.
II. How do we use your personal information?
We may use your personal information for the following purposes:
• Operating, maintaining and improving our website and other online resource;
• Researching, developing, providing and continuously improving our products and services;
• Conducting and managing daily business;
• Academic interaction with healthcare professionals;
• Responding to your inquiries, requests, or communications sent through our website or the contact details made available on our website;
• Providing subscription services for our news, announcements, or investor-related updates;
• Managing and maintaining our relationship and communications with business contacts who reach us through our website;
• Recruiting and human resource management;
• Internal compliance management，audit，record-keeping; and
• Complying with applicable PRC laws and regulations, for example, monitoring and reporting adverse events for purposes of performing drug quality management responsibilities, providing medical information and dealing with product complaints, etc..
We will process personal information only to the extent necessary for the relevant purpose. Where required by applicable law, we will obtain your consent or separate consent before processing your personal information or sensitive personal information. Where a third-party platform or service is used in connection with a particular function, the relevant third party may process your personal information in accordance with its own privacy policy and applicable law.
III. How do we entrust, share, transfer and publicly disclose your personal information?
1. Entrustment
We may entrust our business partners with the processing of your personal information for the purpose(s) described in this Policy. We will enter into appropriate confidentiality, data processing and security agreements with such entrusted parties and require them to process personal information in accordance with our instructions , this Policy and applicable PRC laws and regulations.
2. Sharing and public disclosure
For the purpose(s) described in this Policy, we will share or publicly disclose your personal information only where permitted by applicable PRC laws and regulations and, where required, after obtaining your consent or separate consent. Such circumstances may include:
• Sharing your personal information among our affiliates and subsidiaries where necessary for legitimate business, management, compliance, or operational purposes;
• Sharing your personal information with vendors or business partners (such as conference service providers, travel service providers, data service providers, banking or insurance institutions, other professional service organizations, to the extent necessary for the relevant purpose); and
• Disclosing your personal information to the extent that it is permitted or required by applicable PRC laws and regulations or for the purpose of assisting with investigations by judicial, regulatory or law enforcement authorities.
• other circumstances permitted by applicable PRC laws and regulations.
If you submit your information through or in connection with a third-party platform or service referred to on our website, the relevant third party may independently process your personal information in accordance with its own privacy policy and applicable law.
3. Transfer
We will not transfer your personal information to any other company, entity or individual unless otherwise permitted by applicable law and, where required, after obtaining your consent. Further, in the event of a merger, acquisition, insolvency, reorganization, division, dissolution, bankruptcy, or similar transaction, we will require the new processor of your personal information to continue to be bound by this Policy or we will require the new processor to obtain your consent again.
IV.How do we provide your personal information across borders?
In principle, personal information that we collect and generate in the course of our operations within the territory of the PRC will be stored within the PRC. In certain circumstances, it may be necessary for us to provide your personal information to recipients outside the PRC in connection with our business operations, website functions, or communications, where permitted by applicable PRC laws and regulations. As required by applicable laws and regulations regarding the protection of personal information, we will provide you with the required notice and obtain your separate consent before providing your personal information across any border, unless otherwise permitted by law. We will use lawful cross-border transfer mechanisms to transfer your personal information oversea and will take necessary measures to ensure that the oversea recipients provide a level of protection required by applicable PRC laws and regulations.
You may obtain more information about cross-border transfers of personal information and oversea recipients through the contact methods referred to in this Policy.
V. How do we store your personal information?
We will retain your personal information for the minimum period necessary to achieve the purposes described in this Policy ,unless a longer retention period is required or permitted by applicable PRC laws and regulations. Upon expiration of the applicable retention period, we will promptly delete or anonymize your personal information in accordance with applicable PRC laws and regulations. Our criteria for determining the period for which personal information shall be retained include:
• Applicable laws, regulations and other relevant requirements;
• The period of time needed for us to provide services, maintain business relations or interact with you; and
• The period of time needed for us to perform relevant agreements or fulfil the purposes described in this Policy.
VI. What security measures do we take to protect your personal information?
In accordance with applicable PRC laws, regulations, and the requirements of relevant national standards, we take reasonable and appropriate security and precautionary measures to protect the personal information we process against unauthorized access, public disclosure, use, modification, destruction or loss of data. However, you are also responsible for taking appropriate measures to protect the security of the devices, systems, and networks you use when accessing our website or communicating with us.
VII. Your rights
In accordance with the requirements of the applicable PRC laws and regulations, you may have the following rights in respect of your personal information:
• To know about and make decisions regarding the processing of your personal information;
• To access or copy your personal information;
• To correct or supplement your personal information;
• To delete your personal information;
• To request for explanation of rules regarding processing of personal information; and
• To change the scope of your consent or revoke your consent , where processing is based on your consent.
If you wish to exercise your rights with respect to personal information, you may contact us through the contact information listed in this Policy and we will respond to any request in accordance with applicable relevant laws and regulations. When you exercise the above rights, we may verify your identity to safeguard the security of your personal information. Subject to applicable PRC laws and regulations, there may be circumstances where we are unable to respond to all or part of your request.
VIII. How do we process the personal information of minors?
For the purposes of this Policy and in accordance with applicable PRC laws and regulations, our products, websites and services are not targeted at minors under the age of 14. Minors under the age of 14 should not provide personal information to us without the consent of a parent or legal guardian.
If a minor's personal information is collected with the consent of a parent or legal guardian, we will process the information only when permitted by law, with the express consent of the parent or legal guardian, or necessary for the protection of the minor. If we discover that we have collected personal information without obtaining verifiable prior consent of a parent or legal guardian, we will seek to delete the data as soon as possible.
IX. Updates of the Policy
We may revise our Privacy Policy from time to time. We will post the updated version on our website and update the “Last Updated” date above or below this Policy.
Last updated: March 30, 2026.
X. How to contact us?
If you have any questions, comments or suggestions concerning this Policy, or any questions or concerns about our processing of your personal information, you may contact us in the following ways:
Address: 11/F, B8 Building, No.188 Yizhou Rd, Xuhui District, Shanghai
Tel.: 021- 33395800
Postal Code: 200233
Email: PR@lshhqj.com
Cookies Policy
When you visit our website, we may place small data files known as “cookies” on your device. Cookies enable our website to recognize your browser and help us understand how visitors use the site.
Cookies and similar technologies used on this website may collect online identifiers, device information, browser information, IP address, and information about how you interact with the website. In certain circumstances, such information may constitute personal information or may be associated with you under applicable PRC laws and regulations. Information collected through cookies is used for purposes such as ensuring website operation, maintaining security, analyzing traffic and performance, remembering user preferences, and improving website content and user experience.
You may choose to accept or decline cookies by adjusting your browser settings or through any cookie banner or preference center made available on our website, if applicable. Please note that disabling cookies may affect the functionality of certain parts of the website.
For more information about how we process personal information, please refer to our Privacy Notice.
Some cookies may be provided by third parties. Where third-party cookies or similar technologies are used, such third parties may process the relevant information in accordance with their own privacy policies and applicable PRC laws and regulations.
Accessibility
Shanghai Henlius Biotech, Inc. (“Henlius”) is committed to improving the accessibility and user friendliness of its website for all visitors.
We strive to ensure that the content on our website can be accessed and used by individuals with diverse needs, including those who rely on assistive technologies. As our website continues to evolve, we recognize that accessibility is an ongoing effort, and we are continuously working to improve usability and accessibility across our digital platforms.
If you experience difficulty accessing any part of our website, or have suggestions on how we can enhance accessibility, we welcome your feedback. To help us respond effectively, please include the specific webpage address (URL) and a brief description of the issue encountered.
Contact us:
Email: PR@lshhqj.com
(Please include “Website Accessibility” in the subject line)
Henlius will make reasonable efforts to review accessibility-related feedback and improve the overall online experience for all users. While we strive to improve accessibility, we do not guarantee that every page or feature will be fully accessible to every user in all circumstances.
Terms of Use
This website (http://www.lshhqj.com/) is developed and operated by Shanghai Henlius Biotech, Inc. (“Henlius”). Please read these Terms of Use carefully before accessing or using this website. By accessing, browsing or using this website, you acknowledge that you have read, understood and agreed to be bound by these Terms of Use and applicable PRC laws and regulations.
Henlius reserves the right to modify or update these Terms of Use at any time. Any updated version will be posted on this website with a revised “Last Updated” date. Please review them periodically for updates.
Prohibited Conduct:
You shall not infringe the lawful rights and interests of Henlius or any third party, nor interfere with or attempt to interfere with the normal operation, security, or integrity of this website by any means. Without limitation, you shall not use this website for any unlawful purpose, attempt unauthorized access to any part of the website or related systems, introduce malicious code, scrape or extract website content through automated means, or otherwise interfere with the website’s operation or security features.
Copyright
All content on this website, including but not limited to text, data, logos, graphics, audio, video and other materials, is owned by Henlius or its respective rights holders, unless otherwise stated. Such content is protected by applicable Chinese and international copyright laws. This website and its content may be accessed and used only for lawful, personal, and non-commercial purposes. Without prior written consent, no entity or individual may copy, reproduce, republish, upload, post, transmit, distribute, modify, create derivative works from, mirror, or otherwise use such content for commercial or public purposes.
Disclaimers
To the fullest extent permitted by applicable PRC laws and regulations, Henlius makes no warranties or representations, express or implied, regarding the content of this website, including but not limited to accuracy, completeness, timeliness or suitability for any particular purpose. Henlius does not undertake any obligation to update the content of this website , except as otherwise required by applicable PRC laws and regulations.
You use this website and any information obtained from it at your own risk. To the fullest extent permitted by applicable PRC laws and regulations, Henlius shall not be liable for any loss or damage arising from the use or inability to use this website, including but not limited to system failures, computer viruses or data loss.
Medical Information
Nothing on this website constitutes medical advice, diagnosisor treatment recommendations. Medical decisions should always be made in consultation with qualified healthcare professionals. Any product-related or disease-related information provided on this website is provided for general informational purposes only and should not be construed as medical advice, diagnosis, or treatment recommendations; any product information is subject to the approved prescribing information and applicable local laws and regulations.
Third Party Websites
This website may contain links to third party websites for convenience. Henlius is not responsible for the content, availability, privacy practices, terms or use of such third-party websites. Access to third party websites is at your own risk.
Privacy
Henlius respects your privacy. Please refer to our Privacy Notice for details.
Governing Law
These Terms of Use shall be governed by the laws of the People’s Republic of China.
Last updated: March 30, 2026